FAM180B Inhibitors
FAM180B inhibitors encompass a range of compounds that influence various cellular signaling pathways and processes. Staurosporine, a broad-spectrum kinase inhibitor, can impede kinase activity essential for the proper functioning of FAM180B. This action can result in the inactivation of downstream signaling required for FAM180B-mediated cellular functions. Similarly, both wortmannin and LY294002 target the PI3K/AKT pathway, which could diminish the phosphorylation status and functional activity of FAM180B, assuming it operates as a downstream effector in this signaling cascade. Inhibition of this pathway by these compounds can lead to decreased functional activity of FAM180B.
U0126 and PD98059 are selective inhibitors of the MEK1/2 and by extension the MAPK/ERK pathway. If FAM180B is regulated through this route, its activity would be lessened as a result of inhibiting these kinases. SB203580 and SP600125, which target p38 MAPK and JNK respectively, can disrupt stress response signaling and other JNK-regulated processes that might involve FAM180B, leading to a reduction in its functional activity. Rapamycin, an mTOR inhibitor, can suppress the mTOR signaling that is central to cell growth and metabolism, which may reduce FAM180B activity if it is linked to this pathway. Bortezomib and MG132 are proteasome inhibitors that prevent the degradation of proteins, potentially affecting FAM180B if its activity is controlled by proteasomal degradation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor known to block a wide range of kinases. FAM180B function can be linked to kinase signaling cascades, and staurosporine inhibition of these kinases can inactivate downstream signaling required for FAM180B's role in cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a specific phosphatidylinositol 3-kinase (PI3K) inhibitor. By inhibiting PI3K, wortmannin can attenuate the PI3K/AKT pathway, potentially diminishing the phosphorylation status and functional activity of FAM180B if it is a downstream effector. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to wortmannin, that can reduce AKT activation. Since AKT can phosphorylate numerous proteins, inhibition by LY294002 may decrease FAM180B activity if it relies on AKT-mediated phosphorylation for function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, enzymes in the MAPK pathway, which can affect proteins regulated by this pathway. If FAM180B is modulated by the MAPK pathway, U0126 can lead to decreased FAM180B activity by inhibiting the pathway's kinase cascade. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific MEK inhibitor that prevents the activation of MAPK/ERK. This inhibition can result in reduced activity of FAM180B if it is a part of the signaling processes governed by the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. The inhibition of p38 MAPK can disrupt stress response signaling, potentially reducing FAM180B activity if it is implicated in cellular responses to stress mediated by p38. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK family. JNK signaling influences various cellular functions; thus, SP600125's inhibition of JNK can decrease FAM180B activity if FAM180B is involved in JNK-regulated processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central regulator of cell growth and metabolism. If FAM180B activity is coupled to mTOR signaling, rapamycin can reduce its functional activity by inhibiting mTOR pathway signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of regulatory proteins and subsequent alteration of signaling pathways. Inhibition of the proteasome may impact FAM180B function if it is regulated by proteasome-mediated degradation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to increased cytosolic calcium levels, affecting calcium-dependent signaling pathways. Elevated calcium can inhibit FAM180B activity if it is negatively regulated by calcium signaling. | ||||||